About GLP-1 (7-37)
Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.
GLP-1(7-37) is the native 30-amino-acid active form of glucagon-like peptide 1, an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, that acts at GLP-1 receptors throughout the body to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, reduce appetite, and protect beta-cell mass; it is the endogenous ligand underlying the pharmacology of the GLP-1 receptor agonist drug class. The GLP-1 receptor is expressed on pancreatic beta cells, hypothalamic appetite-regulating neurons, gastric enteric neurons, and cardiovascular tissue; GLP-1(7-37) activates cAMP/PKA signaling in beta cells to potentiate insulin release strictly during hyperglycemia, providing intrinsic hypoglycemia protection, and centrally reduces caloric intake through satiety signaling. A randomized controlled trial of continuous subcutaneous native GLP-1 infusion in patients with type 2 diabetes demonstrated significant reductions in plasma glucose and appetite, confirming receptor-mediated effects of the native peptide in humans; the peptide's very short plasma half-life of approximately 2 minutes due to rapid DPP-IV degradation makes continuous infusion the only practical administration route for the native form. Native GLP-1(7-37) has no FDA approval as a drug; FDA-approved GLP-1 receptor agonists — including semaglutide, liraglutide, dulaglutide, and tirzepatide — are chemically modified DPP-IV-resistant analogs developed to overcome the native peptide's pharmacokinetic limitations, and research-grade native GLP-1 is used exclusively as a tool compound in metabolic pharmacology studies.
GLP-1 (7-37) Benefits & Research Areas
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 moderate
1 RCT · 1 Cohort
Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.
Protein Sci · 2026
# Summary Research found that engineered compact fusion tags can significantly improve the recombinant expression and recovery of GLP-1(7-37) precursors in *E. coli* by optimizing the mass ratio between the target peptide and its cleavable protein tag. This study demonstrated that a specifically designed 4.0 kDa tag (LP8) achieved the highest yields by balancing inclusion body formation with minimal tag mass, offering a scalable manufacturing approach for GLP-1 analogs and other small peptide therapeutics.
GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by reduction of pre-hepatic insulin extraction
Diabetes Care · 1999
Research in a small randomized crossover trial found that continuous 48-hour GLP-1(7-37) infusion reduced fasting blood glucose, stimulated insulin secretion, suppressed glucagon, and reduced appetite in obese patients with type 2 diabetes, establishing the metabolic basis for GLP-1 receptor agonism as a therapeutic strategy.
GLP-1 (7-37) Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy GLP-1 (7-37) — Providers & Availability
30 providersClinics
10 providersBluePath Longevity
United StatesView →Incite Health and Wellness
United StatesView →Longevity Clinic
United StatesView →Regain Functional Medicine and Aesthetics
United StatesView →Reset Aesthetics & Wellness
United StatesView →Vitality Integrative Skin Clinic
United StatesView →Dr. Louis Peter Re, JR
United StatesView →Dr. Wendy Weintrob
United StatesView →Progressive Medical Care
United StatesView →Pura Vida Body & Mind Spa
United StatesView →
Stay updated on verified GLP-1 (7-37) providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — GLP-1 (7-37)
GLP-1(7-37) is the native 30-amino-acid active form of glucagon-like peptide 1, an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, that acts at GLP-1 receptors throughout the body to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, reduce appetite, and protect beta-cell mass; it is the endogenous ligand underlying the pharmacology of the GLP-1 receptor agonist drug class. The GLP-1 receptor is expressed on pancreatic beta cells, hypothalamic appetite-regulating neurons, gastric enteric neurons, and cardiovascular tissue; GLP-1(7-37) activates cAMP/PKA signaling in beta cells to potentiate insulin release strictly during hyperglycemia, providing intrinsic hypoglycemia protection, and centrally reduces caloric intake through satiety signaling.
appetite suppression, insulin sensitivity, blood glucose regulation.
Research on GLP-1 (7-37) primarily documents effects related to appetite suppression and insulin sensitivity and blood glucose regulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for GLP-1 (7-37) include thyroid condition, pregnant or nursing. This is educational information only — consult a qualified healthcare professional before use.
30 providers in the directory currently offer GLP-1 (7-37).
# Summary Research found that engineered compact fusion tags can significantly improve the recombinant expression and recovery of GLP-1(7-37) precursors in *E. coli* by optimizing the mass ratio between the target peptide and its cleavable protein tag. This study demonstrated that a specifically designed 4.0 kDa tag (LP8) achieved the highest yields by balancing inclusion body formation with minimal tag mass, offering a scalable manufacturing approach for GLP-1 analogs and other small peptide therapeutics.